South Korea
· Delayed Price · Currency is KRW CJ Bioscience Statistics
Total Valuation
CJ Bioscience has a market cap or net worth of KRW 92.22 billion. The enterprise value is 58.51 billion.
| Market Cap | 92.22B |
| Enterprise Value | 58.51B |
Important Dates
The next estimated earnings date is Thursday, March 20, 2025.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CJ Bioscience has 9.11 million shares outstanding. The number of shares has increased by 45.44% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 9.11M |
| Shares Change (YoY) | +45.44% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.08% |
| Owned by Institutions (%) | 0.12% |
| Float | 555,784 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 23.26 |
| PB Ratio | 1.92 |
| P/TBV Ratio | 2.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.71 |
| EV / Sales | 14.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.14 |
Financial Position
The company has a current ratio of 3.11, with a Debt / Equity ratio of 0.18.
| Current Ratio | 3.11 |
| Quick Ratio | 3.01 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.31 |
| Interest Coverage | -43.88 |
Financial Efficiency
Return on equity (ROE) is -36.64% and return on invested capital (ROIC) is -29.09%.
| Return on Equity (ROE) | -36.64% |
| Return on Assets (ROA) | -24.98% |
| Return on Capital (ROIC) | -29.09% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.05 |
| Inventory Turnover | 17.39 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.26% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -32.26% |
| 50-Day Moving Average | 11,270.00 |
| 200-Day Moving Average | 12,913.10 |
| Relative Strength Index (RSI) | 42.63 |
| Average Volume (20 Days) | 332,813 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CJ Bioscience had revenue of KRW 3.97 billion and -21.62 billion in losses. Loss per share was -2,370.64.
| Revenue | 3.97B |
| Gross Profit | 392.58M |
| Operating Income | -31.45B |
| Pretax Income | -21.62B |
| Net Income | -21.62B |
| EBITDA | -26.96B |
| EBIT | -31.45B |
| Loss Per Share | -2,370.64 |
Balance Sheet
The company has 42.23 billion in cash and 8.51 billion in debt, giving a net cash position of 33.71 billion or 3,699.59 per share.
| Cash & Cash Equivalents | 42.23B |
| Total Debt | 8.51B |
| Net Cash | 33.71B |
| Net Cash Per Share | 3,699.59 |
| Equity (Book Value) | 48.07B |
| Book Value Per Share | 5,275.11 |
| Working Capital | 29.97B |
Cash Flow
In the last 12 months, operating cash flow was -26.30 billion and capital expenditures -1.04 billion, giving a free cash flow of -27.34 billion.
| Operating Cash Flow | -26.30B |
| Capital Expenditures | -1.04B |
| Free Cash Flow | -27.34B |
| FCF Per Share | -3,000.70 |
Margins
| Gross Margin | 9.90% |
| Operating Margin | -792.92% |
| Pretax Margin | -544.89% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CJ Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -45.44% |
| Shareholder Yield | -45.44% |
| Earnings Yield | -23.43% |
| FCF Yield | -29.65% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CJ Bioscience has an Altman Z-Score of 0.77. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.77 |
| Piotroski F-Score | n/a |